Dexamethasone acetate is under clinical development by Oculis and currently in Phase II for Cystoid Macular Edema. According to GlobalData, Phase II drugs for Cystoid Macular Edema have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dexamethasone acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dexamethasone acetate overview
Dexamethasone acetate (DexNP, OC-118, OCS-01) is under development for the treatment of macular edema, diabetic macular edema and post cataract operation inflammation and pain. The tehrapeutic candidate is formulated as eye drop suspension and administered through ophthalmic route of administration. It is a nanoparticle composed of gamma-cyclodextrin dexamethasone complex. Dexamethasone is synthetic glucocorticoids which target glucocorticoid receptors. The drug candidate is a complex of drug and cyclodextrin nanoparticle developed based on solubilizing nano-particle (SNP) drug-delivery technology and OPTIREACH. It was also under development of posterior and intermediate uveitis, glaucoma and ocular inflammation after surgery.
Oculis overview
Oculis is a biopharmaceutical company that develops and commercializes topical treatments for acute optic neuritis, chronic back, glaucoma and front-of-the-eye ophthalmic diseases. The company is headquartered in Zug, Switzerland.
For a complete picture of Dexamethasone acetate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
